医学
骨髓
前列腺癌
免疫组织化学
活检
病理
免疫系统
骨转移
免疫疗法
前列腺
体内
癌症
放射治疗
川地68
转移
核医学
免疫原性
肿瘤科
临床终点
前列腺特异性抗原
正电子发射断层摄影术
泌尿科
内科学
原发性肿瘤
抗原
流式细胞术
组织学
免疫检查点
PET-CT
作者
Sui Wai Ling,Anouk de Jong,Mark A.J. Gorris,Marcel Segbers,Laura H. Graven,Marjolein van Driel,Geert J.L.H. van Leenders,Khrystany T. Isebia,Marjolijn N. Lub–de Hooge,Paul Hamberg,Niven Mehra,Mandy van Brakel,Ronald de Wit,Reno Debets,Elisabeth de Vries,Tessa Brabander,Jolanda De Vries,Astrid Aplonia Maria Van Der Veldt
标识
DOI:10.1007/s00259-026-08175-9
摘要
Abstract Purpose Most patients with metastatic castration-resistant prostate cancer (mCRPC) do not benefit from treatment with immune checkpoint inhibitors targeting programmed cell death (ligand) 1 (PD-(L)1). Radiation might improve response to immunotherapy by increasing the immunogenicity of prostate cancer. The objective of this study was to investigate radium-223-mediated changes in the micro- and macroenvironment of mCRPC. Methods In this prospective, multicenter study (ICTRP NL-OMON26890), 28 patients with mCRPC and predominantly bone metastases were treated with radium-223, according to standard-of-care. Primary endpoint was failure-free survival (FFS). Imaging included sequential positron emission tomography (PET) with gallium-68 prostate-specific membrane antigen ( 68 Ga-PSMA) and zirconium-89 atezolizumab ( 89 Zr-atezolizumab) to quantify whole-body expression of PD-L1 in vivo (SUV mean/max ). Paired PET analysis included nine patients. The immune status of patients was characterized in biopsies from bone metastases and in blood using (multiplex) immunohistochemistry (IHC) and flow cytometry, respectively. Sequential biopsy analysis included two patients. Results 89 Zr-atezolizumab uptake in 68 Ga-PSMA positive bone metastases showed high intra- and inter-patient heterogeneity. In the total volume of 68 Ga-PSMA-positive bone lesions, the median SUV mean of 89 Zr-atezolizumab was 2.5 (IQR 0.9–3.4) at baseline and 0.9 (IQR 0.5–2.5) after three cycles of radium-223, which was higher than the physiological uptake in bone marrow at baseline and after treatment with radium-223. After three cycles of radium-223, 89 Zr-atezolizumab uptake decreased in bone metastases, independent of response on 68 Ga-PSMA PET, and the number of lymphocytes in tumor tissue and blood decreased concomitantly. Conclusions Treatment of mCRPC bone metastases with radium-223 results in a significant decrease of in vivo PD-L1-expression on PET imaging and a decrease in immune cells in bone metastases and blood. These findings indicate that treatment with alpha emitting radium-223 alters the immune microenvironment, thereby potentially reducing the efficacy of PD-(L)1 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI